Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis
Objective To evaluate the efficacy and safety of ferric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease（CKD）,and provide evidence-based basis for clinical medication.Methods The literature on randomized controlled trials（RCTs） relating to treatment of hyperphosphate...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2020-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57905104&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323608022712320 |
|---|---|
| author | WANG Shan-shan WEN Tong ZHANG Xin-zhou |
| author_facet | WANG Shan-shan WEN Tong ZHANG Xin-zhou |
| author_sort | WANG Shan-shan |
| collection | DOAJ |
| description | Objective To evaluate the efficacy and safety of ferric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease（CKD）,and provide evidence-based basis for clinical medication.Methods The literature on randomized controlled trials（RCTs） relating to treatment of hyperphosphatemia in patients with CKD was searched from the databases of Cochrane Library,PubMed,EMBase,and Web of Science.We used software RevMan5.3 to perform the Meta-analysis of the included RCTs to compare the efficacy and safety of ferric citrate versus placebo or other phosphorus binding agents in treatment of hyperphosphatemia in patients with CKD.Results A total of 1906 cases in 11 RCTs was included.Our meta-analysis showed that,compared to the control group,ferric citrate did better in alleviating hyperphosphatemia [MD=-0.66,95%CI（-0.77,-0.55）,P<0.01],where it reduced serum phosphorus compared with placebo [MD=-1.43,95%CI（-2.20,-0.66）,P<0.01] and was not inferior to other phosphorus binders [MD=0.10,95%CI（-0.11,0.30）,P=0.36].Furthermore,ferric citrate significantly improved hemoglobin,ferritin,transferrin saturation and hematocrit.In terms of adverse effects,compared with the placebo group or other phosphorus binder groups,in the ferric citrate group the incidence of diarrhea was higher and the incidence of constipation and bloating did not differ significantly between ferric citrate and placebo groups or other phosphorus binder groups.Conclusions Ferric citrate can effectively reduce serum phosphorus in patients with CKD and hyperphosphatemia,and also improve renal anemia. |
| format | Article |
| id | doaj-art-eea74a50f52141c5889d0fa878aab5aa |
| institution | Kabale University |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2020-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-eea74a50f52141c5889d0fa878aab5aa2025-08-20T03:48:58ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902020-01-0195596457905104Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysisWANG Shan-shanWEN TongZHANG Xin-zhouObjective To evaluate the efficacy and safety of ferric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease（CKD）,and provide evidence-based basis for clinical medication.Methods The literature on randomized controlled trials（RCTs） relating to treatment of hyperphosphatemia in patients with CKD was searched from the databases of Cochrane Library,PubMed,EMBase,and Web of Science.We used software RevMan5.3 to perform the Meta-analysis of the included RCTs to compare the efficacy and safety of ferric citrate versus placebo or other phosphorus binding agents in treatment of hyperphosphatemia in patients with CKD.Results A total of 1906 cases in 11 RCTs was included.Our meta-analysis showed that,compared to the control group,ferric citrate did better in alleviating hyperphosphatemia [MD=-0.66,95%CI（-0.77,-0.55）,P<0.01],where it reduced serum phosphorus compared with placebo [MD=-1.43,95%CI（-2.20,-0.66）,P<0.01] and was not inferior to other phosphorus binders [MD=0.10,95%CI（-0.11,0.30）,P=0.36].Furthermore,ferric citrate significantly improved hemoglobin,ferritin,transferrin saturation and hematocrit.In terms of adverse effects,compared with the placebo group or other phosphorus binder groups,in the ferric citrate group the incidence of diarrhea was higher and the incidence of constipation and bloating did not differ significantly between ferric citrate and placebo groups or other phosphorus binder groups.Conclusions Ferric citrate can effectively reduce serum phosphorus in patients with CKD and hyperphosphatemia,and also improve renal anemia.http://www.lcszb.com/thesisDetails?columnId=57905104&Fpath=home&index=0Ferric citrateChronic kidney diseaseHyperphosphatemiaMeta-analysis |
| spellingShingle | WANG Shan-shan WEN Tong ZHANG Xin-zhou Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis Linchuang shenzangbing zazhi Ferric citrate Chronic kidney disease Hyperphosphatemia Meta-analysis |
| title | Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis |
| title_full | Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis |
| title_fullStr | Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis |
| title_full_unstemmed | Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis |
| title_short | Efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease:a Meta-analysis |
| title_sort | efficacy and safety offerric citrate in treatment of hyperphosphatemia in patients with chronic kidney disease a meta analysis |
| topic | Ferric citrate Chronic kidney disease Hyperphosphatemia Meta-analysis |
| url | http://www.lcszb.com/thesisDetails?columnId=57905104&Fpath=home&index=0 |
| work_keys_str_mv | AT wangshanshan efficacyandsafetyofferriccitrateintreatmentofhyperphosphatemiainpatientswithchronickidneydiseaseametaanalysis AT wentong efficacyandsafetyofferriccitrateintreatmentofhyperphosphatemiainpatientswithchronickidneydiseaseametaanalysis AT zhangxinzhou efficacyandsafetyofferriccitrateintreatmentofhyperphosphatemiainpatientswithchronickidneydiseaseametaanalysis |